



10/526759
PCT/PTO 04 MAR 2005
#2
INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

REC'D 03 OCT 2003
WIPO PCT


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

I also certify that the attached copy of the request for grant of a Patent (Form 1/77) bears an amendment, effected by this office, following a request by the applicant and agreed to by the Comptroller-General.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed


Dated 11 July 2003

BEST AVAILABLE COPY

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Patents Form 1/77

Patents Act 1977
(Rule 16)



The
**Patent
Office**

1/77
05 SEP 02 17:29:15-1 D00524
P01/770000.00-0220581.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP10 8QQ

1. Your reference **4-32634P1**

2. Patent application number
(The Patent Office will fill in this part) **0220581.3** **04 SEP 2002**

3. Full name, address and postcode of the or of each applicant
(underline all surnames) **NOVARTIS AG**
LICHTSTRASSE 35
4056 BASEL
SWITZERLAND

Patent ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

SWITZERLAND

4. Title of invention **Organic compound**

5. Name of your agent (If you have one)

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

B.A. YORKE & CO.
CHARTERED PATENT AGENTS
COOMB HOUSE, 7 ST. JOHN'S ROAD
ISLEWORTH
MIDDLESEX TW7 6NH

CRAIG McLean
Novartis Pharmaceuticals
UK Ltd
Patents + Trademarks
Wimblehurst Rd
Horsham
West Sussex RH12 5AG

Patents ADP number (if you know it)

1800001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

Yes

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

(see note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 15 /

Claim(s) 3 /

Abstract

Drawing(s)

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77) ONE /

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application

Signature

Date

B. A. Yorke & Co.

B.A. Yorke & Co.

04 September 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mrs. E. Cheetham

020 8560 5847

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

Organic compound

The present invention relates to novel 1-aza-bicycloalkyl derivatives, to processes for their production, their use as pharmaceuticals and to pharmaceutical compositions comprising them.


More particularly the present invention provides in a first aspect, a compound of formula I



wherein

X is CH₂ or a single bond;

Y is a group of formula



R is a substituted or unsubstituted C₅-C₁₀aryl or substituted or unsubstituted hetero-C₅-C₁₀aryl, N(R¹)(R⁴), or N(R²)(CHR³R⁴);

each of R¹, R² and R³ is independently H, C₁-C₄alkyl, or CF₃;

R⁴ is a substituted or unsubstituted C₅-C₁₀aryl or substituted or unsubstituted hetero-C₅-C₁₀aryl;

in free base or acid addition salt form.


C₅-C₁₀aryl or hetero-C₅-C₁₀aryl residues are to be understood as aromatic residues optionally substituted by one or more substituents selected from halogen, e.g. F, Cl, Br, I; CN, or C₁-C₂alkyl which again can be unsubstituted or substituted by halogen; e.g. trifluoromethyl; or C₁-C₄alkoxy, or condensed, e.g. to a benzo[1,3]dioxole or 2,3-dihydrobenzo[1,4]dioxine and/or to a further heterocyclic ring. Hetero-C₅-C₁₀aryl is an aromatic heterocyclic system comprising one, two or three hetero atoms selected from N, O, S, e.g. a 5 or 7 membered aromatic heterocyclic residue optionally condensed, e.g. to 1 or 2 phenyl rings and/or to a

further heterocyclic ring. Examples of C_5 - C_{10} aryl or hetero- C_5 - C_{10} aryl residues as mentioned above include phenyl, naphthyl, thiophenyl and isobenzofuranyl.

On account of the asymmetrical carbon atom(s) present in the compounds of formula I and their salts, the compounds may exist in optically active form or in form of mixtures of optical isomers, e.g. in form of racemic mixtures. All optical isomers and their mixtures including the racemic mixtures are part of the present invention.

In formula I the following significances are preferred independently, collectively or in any combination or sub-combination:

(a) X is CH_2 ;



(c) R is 1- isobenzofuranyl or substituted or unsubstituted phenyl, e.g. monosubstituted by a chlorine or fluorine in position 2, 3 or 4, CF_3 in position 2 or 3, methoxy in position 2; trifluoromethoxy in position 3; benzo[1,3]-dioxole; 2,3-dihydrobenzo[1,4]-dioxine; cyano; or disubstituted, e.g. by a fluorine in position 2 and 5, 3 and 5 or chlorine in position 2 and fluorine in position 6.

In addition to the foregoing the present invention also provides a process for the production of a compound of formula I, which process comprises the step of

reacting a compound of formula II



wherein Y and R are as defined above and z is a leaving group, e.g. F, Cl, Br, I or OSO_2CF_3 , with a compound of formula III



wherein X is as defined above,

and recovering the so obtained compound of formula I in free base or acid addition salt form.

The reaction may be carried out in accordance with standard procedures, for example as illustrated in the Examples.


Compounds of formula II are known or may be prepared from corresponding known compounds, e.g. as described in the Examples, e.g. in analogy to Coates WJ, McKillop A (1992) Synthesis 334-342. The compounds of formula III are known.

Alternatively, the compounds of formula I'



wherein

X and R are as defined above and Y' is



produced by a process comprising the step of

reacting a compound of formula IV




wherein Y', z and X are as defined above,
with a compound of formula V



wherein R is as defined above,
and recovering the so obtained compound of formula I' in free base or acid addition salt form.

Compounds of formula IV are known or may be prepared from corresponding known compounds, e.g. as described in Example 17, e.g. by reacting compounds of formula III with compounds of formula II';



Compounds of formula V (e.g. unsubstituted or substituted phenylboronic acids) are known or may be prepared from corresponding known compounds.

Working up the reaction mixtures according to the above processes and purification of the compounds thus obtained may be carried out in accordance to known procedures.

Acid addition salts may be produced from the free bases in known manner, and vice-versa. Suitable acid addition salts for use in accordance with the present invention include for example the hydrochloride.

Compounds of formula I in optically pure form can be obtained from the corresponding racemates according to well-known procedures, e.g. HPLC with chiral matrix. Alternatively, optically pure starting materials can be used.

The compounds of the invention and their pharmaceutically acceptable acid addition salts, hereinafter referred to as agents of the invention, exhibit valuable pharmacological properties when tested in vitro and in animals, and are therefore useful as pharmaceuticals.

In particular, the agents of the invention are $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists.

In functional assays, the agents of the invention display high affinity at the $\alpha 7$ nAChR as shown in the following tests:

- a) A functional assay for affinity at the $\alpha 7$ nAChR is carried out with a rat pituitary cell line stably expressing the $\alpha 7$ nAChR. As a read out, the calcium influx upon stimulation of the receptor is used. In this assay, agents of the invention exhibit pEC_{50} values of about 5 to about 8.
- b) To assess the activity of the agents of the invention on the human neuronal nAChR $\alpha 4\beta 2$, a similar functional assay is carried out using a human epithelial cell line stable expressing the human $\alpha 4\beta 2$ subtype. In this assay, agents of the invention show selectivity for the $\alpha 7$ nAChR subtypes.
- c) To assess the activity of the compounds of the invention on the "ganglionic subtype" and the muscle type of nicotinic receptor, similar functional assays as described under a) are carried out with a human epithelial cell line stably expressing the human ganglionic subtype or a cell line endogenously expressing the human muscle type of nicotinic receptors. In these assays, agents of the invention display no or little activity on the ganglionic and muscle type of nicotinic receptor subtypes.

In the model of mice showing sensory gating deficit (DBA/2-mice) described by S. Leonard et al. in Schizophrenia Bulletin 22, 431-445 (1996), the agents of the invention induce significant sensory gating at concentrations of about 10 to about 40 μM .

The agents of the invention are therefore useful for the prevention and treatment of psychotic disorders such as schizophrenia, mania, depression and anxiety, and for the prevention and treatment of neurodegenerative disorders such as senile dementia, Alzheimer's disease and other intellectual impairment disorders, such as attention deficit hyperactivity disorders (ADHD); Parkinson's disease, Huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, convulsions, Tourette syndrome, OCD (obsessive compulsive disorder), neuropathic, postoperative and inflammatory pain, phantom limb pain, cognition, smoking cessation, memory deficits and dysfunction, learning deficit, panic disorders, narcolepsy, nociception, AIDS dementia, senile dementia, autism, tardive dyskinesia, social phobia, pseudodementia. The usefulness of $\alpha 7$ nAChR agonists in neurodegeneration is documented in the literature, e.g. in Wang et al., J. biol. Chem. 275, 5626-5632 (2000).

For the above indications the appropriate dosage of the agents of the invention will, of course, vary depending upon, for example, the host, the mode of administration and the nature and severity of the condition being treated as well as the relative potency of the particular agent of the invention employed. For example, the amount of active agent required may be determined on the basis of known in vitro and in vivo techniques, determining how long a particular active agent concentration in the blood plasma remains at an acceptable level for a therapeutic effect. In general, satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o. In humans, an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g. from about 50 to 200 mg (70 kg man), conveniently administered once or in divided doses up to 4 x per day or in sustained release form. Oral dosage forms accordingly suitably comprise from about 1.75 or 2.0 to about 700 or 1400 mg of an agent of the invention admixed with an appropriate pharmaceutically acceptable diluent or carrier therefor.

Examples for compositions comprising an agent of the invention include, e.g. a solid dispersion, an aqueous solution, e.g. containing a solubilising agent, a microemulsion and a suspension of, e.g. a hydrochloride salt of a compound of formula I in the range of from 0.1 to 1 %, e.g. 0.5 %. The composition may be buffered to a pH in the range of, e.g. from 3.5 to 9.5, e.g. to pH 4.5, by a suitable buffer.

The agents of the invention are also useful as research chemicals.

For use according to the invention, the agent of the invention may be administered as single active agent or in combination with other active agents, in any usual manner, e.g. orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injection solutions or suspensions.

The pharmaceutical compositions for separate administration of the combination partners and for the administration in a fixed combination, i.e. a single galenical composition comprising at least two combination partners, according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals, including man, comprising a therapeutically effective amount of at least one pharmacologically active combination partner alone or in combination

with one or more pharmaceutically acceptable carries, especially suitable for enteral or parenteral application.

Pharmaceutical compositions contain, for example, from about 0.1 % to about 99.9 %, preferably from about 20 % to about 60 %, of the active ingredients. Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, and furthermore ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar-coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of a combination partner contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.

In particular, a therapeutically effective amount of each of the combination partners may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination. For example, the method of delay of progression or treatment of a proliferative disease according to the invention may comprise (i) administration of the combination partner (a) in free or pharmaceutically acceptable salt form and (ii) administration of a combination partner (b) in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein. The individual combination partners can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. Furthermore, the term administering also encompasses the use of a pro-drug of a combination partner that convert *in vivo* to the combination partner as such. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.

The effective dosage of each of the combination partners employed may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the condition being treated, the severity of the condition being treated. Thus, the dosage regimen is selected in accordance with a variety of factors including the route of

administration and the renal and hepatic function of the patient. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites. In general, satisfactory results in animals are indicated to be obtained at daily dosages of from about 0.01 to about 20.0 mg/kg p.o. In humans, an indicated daily dosage is in the range of from about 0.7 to about 1400 mg/day p.o., e.g. from about 50 to 200 mg (70 kg man), conveniently administered once or in divided doses up to 4 x per day or in sustained release form. Oral dosage forms accordingly suitably comprise from about 1.75 or 2.0 to about 700 or 1400 mg.

In accordance with the foregoing, the present invention also provides:

- (1) An agent of the invention for use as an alpha-7 receptor agonist, for example for use in any of the particular indications hereinbefore set forth;
- (2) A pharmaceutical composition comprising an agent of the invention as active ingredient together with a pharmaceutically acceptable diluent or carrier therefore.
- (2') A pharmaceutical composition for the treatment or prevention of a disease or condition in which alpha-7 receptor activation plays a role or is implicated comprising an agent of the invention and a carrier.
- (3) A method for the treatment of any of particular indication hereinbefore set forth in a subject in need thereof which comprises administering an effective amount of an agent of the invention;
- (3') A method for treating or preventing a disease or condition in which the alpha-7 receptor activation plays a role or is implicated comprising administering to a mammal in need thereof a therapeutically effective amount of an agent of the invention.

(4) The use of an agent of the invention for the manufacture of a medicament for the treatment or prevention of a disease or condition in which the alpha-7 receptor activation plays a role or is implicated;

(5) A method as defined above comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a alpha-7 agonist, e.g. an agent of the invention and a second drug substance, said second drug substance being for example for use in any of the particular indications hereinbefore set forth.

(6) A combination comprising a therapeutically effective amount of a alpha-7 agonist, e.g. an agent of the invention and a second drug substance, said second drug substance being for example for use in any of the particular indications hereinbefore set forth.

The preferred compounds of formula I for use in accordance with the invention are those of Examples 2, 18 and 30 which have a pEC₅₀ value between 7 and 8.


Abbreviations used in the examples:

AcOEt	ethyl acetate
aq.	aqueous
DEAD	diethylazodicarboxylate
DMF	dimethylformamide
EtOH	ethanol
FC	flash chromatography
HV	high vacuum
MeOH	MeOH
RP-HPLC	reversed-phase high performance liquid chromatography
rt	room temperature
rac.	racemate
soln.	solution
TFA	trifluoroacetic acid
THF	tetrahydrofuran

The following Examples illustrate the invention.

Example 1: Preparation of (rac.)-3-[6-(4-fluorophenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane

A solution of (rac.)-3-quinuclidinol (0.007 mole) in dry THF under nitrogen is treated with sodium hydride (60% in mineral oil; 1.1 equiv.). After 1 hr at room temperature, a solution of 3-Chloro-6-(4-fluoro-phenyl)pyridazine (1.0 equiv.) in THF (30 ml) is added, and the reaction mixture heated to reflux for 6 hrs. After cooling to room temperature, the THF is evaporated and the residue dissolved in ethyl acetate (100 ml) and then washed with water (3 × 20 ml), followed by sodium chloride solution (20 ml). The ethyl acetate is dried over anhydrous magnesium sulfate, filtered and evaporated to dryness, and the residual oil purified by silica gel column chromatography (eluent: ethyl acetate-methanol-triethylamine (50:10:2) to afford (rac.)-3-[6-(4-fluorophenyl)-pyridazin-3-yloxy]-1-aza-bicyclo[2.2.2]octane as a colourless solid. ¹H-NMR (400 MHz, CDCl₃): δ = 8.00 (m, 2H), 7.75 (d, 1H), 7.17 (m, 2H), 7.1 (d, 1H), 5.35 (m, 1H), 3.5 (m, 1H), 2.99-2.83 (m, 5H), 2.32 (m, 1H), 1.98 (m, 1H), 1.76-1.68 (m, 2H), 1.46 (m, 1H).



The following compounds of formula I wherein Y is analogy to Example 1:

can be prepared in

Ex.	stereo-chem.	X	R	HPLC rt (min)	[α] _D ²⁵	mp. °C (salt)	M+H ⁺
2	(3R,4S)	bond	phenyl	5.7	-23.5° (0.1% MeOH)	143-145 (no salt)	268
3	(3S,4R)	bond	phenyl	5.7	-26.5° (0.1% MeOH)	145-147 (no salt)	268
4	(S)	CH ₂	phenyl	5.2	-32.5° (0.5% MeOH)	128-130 (no salt)	282.2
5	(R)	o-NO ₂	4-chloro-phenyl	6.2	+29.0° (0.1% MeOH)	175-177 (no salt)	316.2
6	(R)	CH ₂	3-chloro-phenyl	6.2	+38.5° (0.1% MeOH)	98-100 (no salt)	316.2

7	rac.	CH ₂	2-methoxy-phenyl	5.5	N/A	125-128 (no salt)	312.4
8	(R)	CH ₂	4-trifluoromethyl-phenyl	7.0	+28 (0.1% MeOH)	172-175 (no salt)	350.5
9	(R)	CH ₂	2-fluoro-phenyl	5.6	+23.5° (0.1% MeOH)	110-113 (no salt)	300.2
10	(R)	CH ₂	2-chloro-phenyl	5.7	+29.5° (0.1% MeOH)	85-87 (no salt)	316.2
11	(R)	CH ₂	4-fluoro-phenyl	5.7	+39.5° (0.1% MeOH)	146-149 (no salt)	300.2
12	(R)	CH ₂	3-fluoro-phenyl	5.5	+31.5° (0.1% MeOH)	118-121 (no salt)	300.2
13	(R)	CH ₂	3,4-dichloro-phenyl	7.3	+29.5° (0.1% MeOH)	173-175 (no salt)	350.2
14	(R)	CH ₂	3-trifluoromethyl-phenyl	6.9	+23.0° (0.1% MeOH)	112-115 (no salt)	350.3
15	(R)	CH ₂	3,5-dichloro-phenyl	7.3	+31.0° (0.1% MeOH)	127-130 (no salt)	350.2
16	(R)	CH ₂	1-isobenzofuranyl	6.8	+29.0 (0.1% MeOH)	193-195° (no salt)	321.38

Example 17: Preparation of (rac.)-3-(5-Phenyl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane

5-Bromo-2-hydroxy-pyrimidine (400 mg, 2.29 mmol), (rac.)-3-quinuclidinol (432 mg, 3.36 mmol) and triphenylphosphine (890 mg, 3.40 mmol) are dissolved in THF (25 ml). After stirring for 10' at -10°C, a solution of DEAD (522 µl, 3.36 mmol) in THF (20 ml) is added dropwise. The reaction mixture is allowed to warm to rt and is stirred for 16h at rt. The reaction mixture is evaporated to give an orange semi-solid (2.50 g), which is triturated with AcOEt and filtered to give (rac.)-3-(5-bromo-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]-octane as a white solid. The filtrate is purified by FC (silica gel, eluents: AcOEt/MeOH 9:1, then

AcOEt/MeOH/NEt₃ 70:27:3). (rac.)-3-(5-Bromo-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane.

(150 mg, 0.53 mmol), phenylboronic acid (66 mg, 0.54 mmol) and tetrakis(triphenylphosphine)palladium are dissolved in toluene:EtOH 9:1 (15 ml). Na₂CO₃ (225 mg, 2.12 mmol) is dissolved in water (1.5 ml) and added to the reaction mixture, which is heated at 90°C for 20h. After cooling to rt, it is filtered over celite; the toluene layer is separated and washed with brine. The aq. layers are re-extracted with AcOEt, the combined organic extracts are dried over MgSO₄, filtered and the filtrate is evaporated to give a light yellow gum (195 mg) that is purified by FC (silica gel, eluents: AcOEt/MeOH 9:1, then AcOEt/MeOH/NEt₃ 70:27:3) to give a white solid which still contains starting material. A second purification is done by RP-HPLC (Phenomenex RP18 column, gradient 0.08% aq. HCOOH/CH₃CN 95:5 → CH₃CN in 20') to give (rac)-3-(5-phenyl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane as its formate salt.

¹H-NMR (400 MHz, CDCl₃): δ = 8.74 (s, 2H), 8.51 (s, 1H), 7.59-7.45 (m, 5H), 5.35-5.28 (m, 1H), 3.82-3.74 (m, 1H), 3.70-3.14 (m, 5H), 2.62-2.54 (m, 1H), 2.53-2.42 (m, 1H), 2.13-1.91 (m, 2H), 1.87-1.76 (m, 1H); HPLC rt (min): 5.4; mp °C: 108-114; M+H⁺ 282.2.


Example 18: Preparation of (R)-3-(5-Phenyl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]octane

5-Bromo-2-chloro-pyrimidine (400 mg, 2.03 mmol), phenylboronic acid (253 mg, 2.07 mmol) and tetrakis(triphenylphosphine)palladium (118 mg, 0.102 mmol) are dissolved in toluene/EtOH 9:1 (50 ml). Na₂CO₃ (861 mg, 8.12 mmol) is dissolved in water (4 ml) and added to the reaction mixture. The mixture is stirred at 90°C for 19h, cooled to rt and filtered over celite. The toluene layer is separated and washed with brine. The aq. layers are re-extracted with AcOEt; the combined organic extracts are dried over MgSO₄ and filtered. The filtrate is evaporated to give a yellow solid (503 mg), which is purified by FC (silica gel, eluents cyclohexane and AcOEt/cyclohexane 1:9) to give 2-chloro-5-phenyl-pyrimidine.

(R)-3-quinuclidinol (478 mg, 3.76 mmol) is added to a suspension of NaH (164 mg of a 60% dispersion in mineral oil, 4.09 mmol) in DMF (10 ml). The mixture is stirred for 1h at rt. 2-Chloro-5-phenyl-pyrimidine (177 mg, 0.93 mmol) is added and the mixture is heated for 3.5 h at 90°C. The reaction mixture is diluted with toluene and washed with 1M aq. NaOH solution and brine. The aq. layers are re-extracted with toluene (3x). The combined organic extracts are dried over MgSO₄ and filtered. The filtrate is evaporated to give a yellow solid (310 mg), which is purified by FC (silica gel, eluents: AcOEt, then AcOEt/MeOH/NEt₃ 80:18:2). A second purification is done by RP-HPLC (Phenomenex RP18 column, gradient 0.08% aq.

HCOOH \rightarrow 0.08% aq. HCOOH/CH₃CN 80:20 in 10', \rightarrow CH₃CN in 15') to give (*R*)-3-(5-phenyl-pyrimidin-2-yloxy)-1-aza-bicyclo[2.2.2]-octane as its formate salt.

¹H-NMR (400 MHz, DMSO): δ = 8.95 (s, 2H), 8.26 (s, 1H), 7.79-7.71 (*m*, 2H), 7.55-7.42 (*m*, 3H), 5.13-5.06 (*m*, 1H), 3.46-3.36 (*m*, 1H), 2.99-2.75 (*m*, 5H), 2.26-2.20 (*m*, 1H), 1.99-1.88-2.42 (*m*, 1H), 1.81-1.63 (*m*, 2H), 1.56-1.45 (*m*, 1H), HPLC rt (min): 5.4; mp °C: 108-110; $[\alpha]_D^{25} +8.6$ (1.03, MeOH), M+H⁺ 282.2.



The following compounds of formula I wherein Y is analogy to Example 17 or 18:

can be prepared in

Ex.	stereo-chem.	X	R	HPLC rt (min)	$[\alpha]_D^{25}$	mp. °C (salt)	M+H ⁺
19	(S)	CH ₂	phenyl	5.6	-31.0° (0.95% MeOH)	126-129 (no salt)	282.2
20	<i>rac.</i>	CH ₂	2-fluoro-phenyl	5.9	N/A	87-93 (no salt)	300.2
21	<i>rac.</i>	CH ₂	3-chloro-phenyl	6.6	N/A	163-165 (no salt)	316.2
22	<i>rac.</i>	CH ₂	3,4-dichloro-phenyl	3.6	N/A	182-184 (no salt)	350.1
23	<i>rac.</i>	CH ₂	2,4-dichloro-phenyl	3.6	N/A	N/A (oil) (HCl salt)	350.1
24	<i>rac.</i>	CH ₂	3,5-dichloro-phenyl	3.7	N/A	183-184 (no salt)	350.1
25	<i>rac.</i>	CH ₂	3-cyano-phenyl	3.5	N/A	189 (no salt)	307.2
26	<i>rac.</i>	CH ₂	3-trifluoromethyl-phenyl	3.5	N/A	158-159 (no salt)	350.2


Example 27: Preparation of *rac*-3-(6-Phenyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]-octane

Bromine (1.1 ml, 21.41 mmol) is slowly added to a soln. of 2-amino-5-chloropyridine (1.00 g, 7.78 mmol) in 47% aq. HBr (6 ml) at -10°C. An aq. soln. of NaNO₂ (1.57 g, 22.75 mmol) is slowly added. The mixture is stirred for 1h at -10 to -5°C, then for 1h at 5°C. The mixture is neutralised with 5M aq. NaOH soln. maintaining the temperature below 25°C. The orange precipitate is filtered, washed with water and dried in HV to give 2-bromo-5-chloropyridine.


2-Bromo-5-chloropyridine (503 mg, 2.61 mmol), phenylboronic acid (325 mg, 2.67 mmol) and tetrakis(triphenylphosphine)palladium (152 mg, 0.13 mmol) are dissolved in toluene:EtOH 9:1 (65 ml). Na_2CO_3 (1.11 g, 10.47 mmol) is dissolved in water (5.2 ml) and added to the reaction mixture. The mixture is stirred at 90°C for 19h, cooled to room temperature and filtered over celite. The toluene layer is separated and washed with brine. The aq. layers are extracted with AcOEt. The combined organic extracts are dried over MgSO_4 and filtered. The filtrate is evaporated to give a brown solid (733 mg), which is purified by FC (silica gel, eluents cyclohexane and AcOEt/cyclohexane 1:4) to give 5-chloro-2-phenyl-pyridine.

(*rac.*)-3-Quinuclidinol (653 mg, 5.13 mmol) is added to a suspension of NaH (224 mg of a 60% dispersion in mineral oil, 5.59 mmol) in DMF (15 ml). The mixture is stirred for 1h at rt. 5-Chloro-2-phenyl-pyridine (240 mg, 1.27 mmol) is added and the mixture is heated for 4.5 h at 90°C, then for 12h at rt. The reaction mixture is diluted with toluene and washed with 1M aq. NaOH soln. and brine. The aq. layers are re-extracted with toluene (3x). The combined organic extracts are dried over MgSO_4 and filtered. The filtrate is evaporated to give a brown oil (338 mg) which is purified by FC (silica gel, eluents: AcOEt, then AcOEt/MeOH/ NEt_3 50:10:2) to give *rac*-3-(6-phenyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]-octane.



$^1\text{H-NMR}$ (400 MHz, CDCl_3): δ = 8.41-8.37 (*m*, 1H), 7.99-7.94 (*m*, 2H), 7.72-7.66 (*m*, 1H), 7.52-7.46 (*m*, 2H), 7.44-7.38 (*m*, 1H), 7.32-7.23 (*m*, 1H), 4.52-4.46 (*m*, 1H), 3.42-3.32 (*m*, 1H), 3.10-2.80 (*m*, 5H), 2.27-2.21 (*m*, 1H), 2.10-1.96 (*m*, 1H), 1.87-1.77 (*m*, 1H), 1.68-1.58 (*m*, 1H), 1.53-1.42 (*m*, 1H), HPLC *rt* (min): 4.9; mp °C: 75-78; $\text{M}+\text{H}^+$ 281.2.




The following compounds of formula I wherein Y is,



can be prepared in analogy to Example 20:

Ex.	stereo-chem.	X	Y	R	HPLC <i>rt</i> (min)	$[\alpha]_{\text{D}}^{25}$	mp. °C (salt)	$\text{M}+\text{H}^+$
28	<i>rac.</i>	CH_2		phenyl	6.8	N/A	75-80 (no salt)	281.2
29	(<i>R</i>)	CH_2		phenyl	5.4	+34.6° (1.0% MeOH)	78-81 (no salt)	281.2

30	(R)	CH ₂		phenyl	4.2	-19.1 (0.5% MeOH)	226-236 (HCl salt)	281.2
----	-----	-----------------	---	--------	-----	----------------------	-----------------------	-------

HPLC conditions:

for Examples 1-21, 27, 28: Column Phenomenex Luna or Kingsorb C18, 30x4.6 mm, 3 μ M.

Gradient (A {H₂O+ 0.08% HCOOH} B CH₃CN): 0 to 5min: A:B 100:0 to 80:20, 5 to 10 min: 80:20 to 0:100, flow 3.0 ml/min.

for Examples 22-26: Column Waters Xterra MS C18, 50x2.1 mm, 2.5 μ M. Gradient

(A:{H₂O+0.02%TFA}, B:{CH₃CN+0.02%TFA}): 0 to 2 min: A:B 90:10 to 5:95; 2 to 4 min: 5:95, 4 to 5.5 min 5:95 to 10:90, 5.5 to 6 min: 10:90 to 90:10, 6 to 7 min: 90:10, flow 0.35 ml/min.

for Examples 29, 30: Column Waters Xterra MS C18, 150x2.1 mm, 3.5 μ M. Gradient

(A:{H₂O+0.02%TFA}, B:{CH₃CN+0.02%TFA}): 0 to 3 min: A:B 90:10 to 10:90; 3 to 8 min: 10:90, 8 to 9 min: 10:90 to 90:10, 9 to 15 min: 90:10, flow 0.35 ml/min.

Claims:


1. A compound of formula I



wherein

X is CH₂ or a single bond;

Y is a group of formula



R is a substituted or unsubstituted C₅-C₁₀aryl or substituted or unsubstituted hetero-C₅-C₁₀aryl, N(R¹)(R⁴), or N(R²)(CHR³R⁴);

each of R¹, R² and R³ is independently H, C₁-C₄alkyl, or CF₃;


R⁴ is a substituted or unsubstituted C₅-C₁₀aryl or substituted or unsubstituted hetero-C₅-C₁₀aryl;

in free base or acid addition salt form.

2. A process for the preparation of a compound of formula I as defined in claim 1, or a salt thereof, which comprises the step of reacting a compound of formula II



wherein Y and R are as defined in claim 1 and z is a leaving group with a compound of formula III



wherein X is as defined in claim 1,

and recovering the so obtained compound of formula I in free base or acid addition salt form.

3. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use as a pharmaceutical.
4. The compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the prevention and treatment of psychotic and neurodegenerative disorders.
5. A pharmaceutical composition comprising a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent.
6. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the prevention and the treatment of psychotic and neurodegenerative disorders.
7. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for the manufacture of a medicament for the prevention and treatment of psychotic and neurodegenerative disorders.
8. A method for the prevention and treatment of psychotic and neurodegenerative disorders, in a subject in need of such treatment, which comprises administering to such subject a therapeutically effective amount of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form.
9. A compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment or prevention of a disease or condition in which $\alpha 7$ nAChR activation plays a role or is implicated.
10. The use of a compound of claim 1 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment or prevention of a disease or condition in which $\alpha 7$ nAChR activation plays a role or is implicated.
11. A method for treating or preventing a disease or condition in which $\alpha 7$ nAChR activation plays a role or is implicated, in a subject in need of such treatment, which comprises

- 18 -

___ . _ administering to such subject a therapeutically effective amount of a compound of claim 1 in
free base or pharmaceutically acceptable acid addition salt form.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.